Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Cognitive function after sevoflurane- versus propofol-based anaesthesia for on-pump cardiac surgery
ISRCTN ISRCTN44821042
ClinicalTrials.gov identifier
Public title Cognitive function after sevoflurane- versus propofol-based anaesthesia for on-pump cardiac surgery
Scientific title Cognitive function after sevoflurane- versus propofol-based anaesthesia for on-pump cardiac surgery: a randomised controlled trial
Acronym C01
Serial number at source Cogdys1
Study hypothesis The present study was designed to contribute to the question, whether a sevoflurane-based anesthesia concept improves cognitive outcomes in patients undergoing cardiac surgery with cardiopulmonary bypass in comparison to a propofol-based total intravenous anaesthesia.

The secondary objective was to determine if the treatment with sevoflurane in comparison to a propofol-based anaesthesia leads to differences in regional cerebral oxygenation measured with near-infrared spectroscopy (NIRS). Further, differences in the relationship between regional cerebral desaturation and cognitive decline, and differences between anaesthetic regimens regarding relevant clinical outcome-parameters should be investigated.
Lay summary
Ethics approval The Ethical Committee of the University of Luebeck approved in February 2006 (ref: 05-139)
Study design Randomised controlled investigator-blinded trial
Countries of recruitment Germany
Disease/condition/study domain Cardiac surgery, cognitive dysfunction
Participants - inclusion criteria 1. Aged between 18 and 85 years, either sex
2. Elective or urgent cardiac surgery with cardiopulmonary bypass
3. American Society of Anaesthesiologists (ASA) grade I to IV
Participants - exclusion criteria 1. Overt neurological diseases or dementia
2. Significant stenosis of the carotid arteries
3. Pregnancy
4. Disposition for malignant hyperthermia
5. Use of monoamine oxidase-inhibitors
6. Insufficient knowledge of the German language
7. Emergency indication
Anticipated start date 01/09/2006
Anticipated end date 30/09/2008
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants n = 64 for each group, total N = 128
Interventions Anaesthesia protocol 1: intravenous group (PROP):
Induction: etomidate 0.2 - 0.3 mg/kg, sufentanil 1 µg/kg, pancuronium 0.07 - 0.1 mg/kg
Maintenance: remifentanil 0.2 - 0.25 µg/kg/min, propofol 3 - 5 mg/kg/h achieving a bispectral index (BIS) of 40 - 50.

Anaesthesia protocol 2: volatile group (SEVO):
Induction: etomidate 0.2 - 0.3 mg/kg, sufentanil 1 µg/kg, pancuronium 0.07 - 0.1 mg/kg
Maintenance: sevoflurane 0.6 - 1.5 MAC, remifentanil 0.2 - 0.25 µg/kg/min achieving a BIS of 40 - 50
During cardiopulmonary bypass: remifentanil 0.2 - 0.25 µg/kg/min, propofol 3 - 5 mg/kg/h achieving a BIS of 40 - 50

The treatment was carried out throughout the surgical procedure. The follow up was conducted 2, 4 and 6 days after surgery. The total length of hospital stay was recorded post hoc. No follow up after hospital discharge was performed.
Primary outcome measure(s) Cognitive function measured with the abbreviated mental-test (AMT), stroop-test, trail-making-test (TMT), word-lists (WL), and mood-assessment-tests on day 2, 4 and 6 after cardiac surgery
Secondary outcome measure(s) 1. Markers of myocardial, cerebral and renal damage (creatine kinase [CK]/creatine kinase myocardial bands [CK-MB], troponin, high sensitivity troponin [hsTroponin], N-terminal prohormone brain natriuretic peptide [NT-proBNP], neurone specific enolase [NSE], beta-subunit of S100 protein [S100beta], neutrophil gelatinase-associated lipocalin [NGAL], cystatin C [CysC], creatinine), measured 2, 4 and 6 days after surgery
2. Clinical outcome concerning brain, kidney and heart, recorded 6 days after surgery
Sources of funding University of Luebeck (Germany)
Trial website
Publications
Contact name Prof  Matthias  Heringlake
  Address Department of Anesthesiology
University of Luebeck
Ratzeburger Allee 160
  City/town Luebeck
  Zip/Postcode 23538
  Country Germany
  Email heringlake@t-online.de
Sponsor University of Luebeck (Germany)
  Address Ratzeburger Allee 160
  City/town Luebeck
  Zip/Postcode D-23538
  Country Germany
  Sponsor website: http://www.mu-luebeck.de/
Date applied 18/02/2010
Last edited 15/03/2010
Date ISRCTN assigned 15/03/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central